SI-BONE To Report Second Quarter 2020 Financial Results on August 3, 2020

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will announce its Q2 2020 financial results post-market on August 3, 2020. The management team will host a conference call at 1:30 PM PT, accessible via the company’s website. SI-BONE specializes in minimally invasive surgical solutions for sacropelvic disorders, notably through its iFuse Implant System, which addresses chronic low back pain. Supported by numerous clinical studies, the iFuse Implant is the only SI joint fusion device with established insurance coverage for the procedure. Detailed company and product information can be found on their website.

Positive

• The iFuse Implant System is supported by multiple prospective clinical studies, showing improved patient outcomes.
• More than 80 peer-reviewed publications validate the safety and effectiveness of the iFuse Implant.
• Exclusive insurance coverage for the SI joint fusion procedure when using the iFuse Implant System.

Negative

• Potential risks associated with the iFuse Implant System; it may not be suitable for all patients.

SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2020 after market close on Monday, August 3, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment. There are over 80 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 10777.0720.2020

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE report its Q2 2020 financial results?

SI-BONE will report its Q2 2020 financial results after the market closes on August 3, 2020.

What is the iFuse Implant System?

The iFuse Implant System is a medical device for sacroiliac fusion, used in minimally invasive surgeries to treat sacropelvic disorders.

How can I access the Q2 2020 earnings call for SI-BONE?

The Q2 2020 earnings call can be accessed via webcast on SI-BONE's 'Investors' section of their website.

What studies support the iFuse Implant System?

The iFuse Implant System is supported by multiple prospective clinical studies and over 80 peer-reviewed publications.

Is there insurance coverage for the iFuse Implant procedure?

Yes, multiple insurance payors have established coverage for the SI joint fusion procedure when performed with the iFuse Implant System.